Skip to main content

News

ACR: In-Person Urgent vs. Virtual Non-Urgent Medical Care

On April 26, 2020 the American College of Rheumatology (ACR) published a guidance paper to assist rheumatologists and rheumatology health professionals in assessing the need for urgent or face-to-face medical care versus virtual or telehealth patient care.  The driving principals being the need t

Cigarette Smoking and ANCA-Associated Vasculitis

JAMA Internal Medicine has reported that cigarette smoking associated with an increased odds of having antineutrophil cytoplasmic antibody–associated vasculitis (AAV) (especially MPO positive AAV) and is thereby a modifiable risk factor for AAV.

Biologic Dose Cuts Feasible in RA

Many patients with rheumatoid arthritis (RA) who achieved remission or low disease activity on biologic treatment were able to reduce the dose of their biologic, particularly if they were also on methotrexate, a retrospective study found.

Hydroxychloroquine and QTc Prolongation

JAMA Cardiology reports the risk of QT (QTc) prolongation when hydroxychloroquine (HCQ) was given to hospitalized patients with coronavirus disease 2019 (COVID-19), especially when given with azithromycin. 

RheumNow Podcast – Novel COVID Rheum Trials (5.1.20)

Dr. Jack Cush reviews the news and journal articles from the past week. Many interesting early reports on the use of rheumatic drugs, including hydroxychlorquine, IL-6 inhibitors, canakinumab, baricitinib and colchicine. Below are some of the links or citations of interest.

Lenabasum Encouraging in Systemic Sclerosis

The oral cannabinoid receptor type 2 (CB2) agonist lenabasum showed promising results for systemic sclerosis (SSc) in a phase II study.

German Society of Rheumatology COVID Pandemic Recommendations

The Annals of Rheumatic Disease has published the preliminary recommendations of the German Society of Rheumatology for the management of Inflammatory rheumatic diseases patients during the SARS-CoV-2/Covid-19 pandemic. These preliminary recommendations are based on an expert consensus from 17 experienced German rheumatologists.

Rheum Views on the Upside and Downside of COVID-19

The world has been turned upside down in the last 6 weeks. Medicine and rheumatology have certainly changed – a frightening experience for Chicken Little, a disaster for the pessimist, a challenge for the pragmatist and an opportunity for the optimists amongst us. Last week I asked our audience to tell me their “upside or downside of COVID-19”. Read on to see how your peers have operating or thinking.

Rare Inflammatory Syndrome in Kids with COVID-19

Pediatricians are asking the question - could this be a rare manifestation of COVID-19 in children?

IL-6 Inhibitors May Benefit COVID-19 Infection

In the last few days there have been encouraging "preliminary" reports that IL-6 inhibition by either tocilizumab or sarilumab may be efficacious in patients with severe coronavirus infections.

TNF Inhibitors Reduce and Stabilize Coronary Plaque

Arthritis & Rheumatology reports that biologic (bDMARD) use in rheumatoid arthritis may decrease cardiovascular disease risk by retarding coronary plaque formation and progression (especially non‐calcified and low‐attenuation plaque).

High Dose Chloroquine Harmful in Severe COVID-19

JAMA Open Network reports an interim analysis of the Brazilian CloroCovid-19 trial showing thta higher doses of chloroquine (CQ) in the treatment of severe COVID-19 was associated with QTc interval prolongation and increased mortality.

×